2024-09-24 - Analysis Report
## Eli Lilly and Co. (LLY) Stock Analysis Report

**Company Overview:** Eli Lilly and Co. is a global pharmaceutical company that researches, develops, manufactures, and markets pharmaceutical products.

**Performance Summary:**

**1. Relative Performance:**

* **Cumulative Return (LLY):** 892.63%
* **Cumulative Return (VOO):** 132.53%
* **Return Difference:** 760.1 (Max: 781.46, Min: -23.07)
* **Relative Divergence:** 94.26% 

LLY has significantly outperformed the S&P 500 (VOO) over the period considered. The current relative divergence of 94.26% indicates that LLY's performance is near its historical peak relative to VOO.

**2. Recent Price Movement:**

* **Closing Price:** 921.49
* **5-day Moving Average:** 912.62
* **20-day Moving Average:** 928.87
* **60-day Moving Average:** 898.41

The stock is currently trading above its 5-day and 60-day moving averages, suggesting potential upward momentum. However, it is below the 20-day moving average, indicating short-term price consolidation.

**3. Technical Indicators:**

* **RSI:** 37.22 -  This indicates a neutral to slightly oversold condition.
* **PPO:** -0.46 -  This suggests that the price momentum is slightly bearish.
* **Delta_Previous_Relative_Divergence:** -5.74 - This indicates a recent decline in the relative performance compared to the previous period.
* **Expected Return:** 46.37% - This indicates a potential 5-year return based on historical data.

The indicators suggest that LLY might be experiencing a short-term pullback after recent outperformance. However, the long-term outlook remains positive with a potential for significant returns.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue | 
|---|---|---|
| 2024-08-08 | 3.29 | 11.30 B$ |
| 2024-04-30 | 2.49 | 8.77 B$ |
| 2023-11-02 | -0.06 | 9.50 B$ |
| 2023-08-08 | 1.96 | 8.31 B$ |
| 2024-08-08 | 1.96 | 8.31 B$ |

The most recent earnings report for Q2 2024 shows EPS of $3.29, exceeding analyst expectations. Revenue also surpassed expectations, reaching $11.30 billion. This strong performance demonstrates the continued growth and profitability of Eli Lilly.  

**5. Overall Analysis:**

Eli Lilly and Co. has been a strong performer, consistently outperforming the S&P 500. Recent earnings have been impressive, exceeding analyst estimates, and the company continues to show robust growth and profitability. While some technical indicators suggest a potential short-term pullback, the long-term outlook remains positive, supported by the company's strong earnings performance and growth potential. 

**6. Conclusion:**

Despite a recent decline in relative performance, Eli Lilly and Co. remains a strong investment opportunity with a robust track record of exceeding expectations. The company's strong fundamentals, consistent growth, and attractive expected returns make it a compelling choice for investors seeking long-term value. 
